KR920018046A - 아릴(또는 헤테로아릴)피페라지닐부틸아졸 유도체의 제조방법 - Google Patents

아릴(또는 헤테로아릴)피페라지닐부틸아졸 유도체의 제조방법 Download PDF

Info

Publication number
KR920018046A
KR920018046A KR1019920003712A KR920003712A KR920018046A KR 920018046 A KR920018046 A KR 920018046A KR 1019920003712 A KR1019920003712 A KR 1019920003712A KR 920003712 A KR920003712 A KR 920003712A KR 920018046 A KR920018046 A KR 920018046A
Authority
KR
South Korea
Prior art keywords
butyl
piperazinyl
pyrimidinyl
methyl
radical
Prior art date
Application number
KR1019920003712A
Other languages
English (en)
Other versions
KR0124133B1 (ko
Inventor
메르쎄 비달 라몬
프리골라 콘스탄샤 조르디
빠레스 꼬로미나스 쥬앙
Original Assignee
마뇨사스 바레라 엔리께
라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마뇨사스 바레라 엔리께, 라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마 filed Critical 마뇨사스 바레라 엔리께
Publication of KR920018046A publication Critical patent/KR920018046A/ko
Application granted granted Critical
Publication of KR0124133B1 publication Critical patent/KR0124133B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

아릴(또는 헤테로아릴)피페라지닐부틸아졸 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식(Ⅸ)의 화합물과 하기 일반식(Ⅲ)의 화합물과의 반응에 의한 하기 일반식(Ⅰ)의 아릴(또는 헤테로아릴)피페라 지닐부틸아졸 유도체의 제조방법.
    상기의 일반식에서, Ar은 질소 또는 다른 치환체를 가진 아릴류, 다른 치환체를 가진 2-피리미딘, 2-N-메틸이미다졸 및 3-(1,2-벤즈이소티아졸)로부터 선택되어지는 방향족 라디칼을 나타내며, Z1은 질소원자 또는 C-R1로 표현되어질 수 있고 선택적으로 치환되어질 수 있는 탄소원자, Z2는 질소원자 또는 C-R2로 표현되어질 수 있고 선택적으로 치환되어질 수 있는 탄소원자, Z4는 질소원자 또는 C-R4로 표현되어질 수 있고 선택적으로 치환되어질 수 있는 탄소원자, R1, R2, R3, R4는 동일하거나 다를 수 있으며, 또 다른 방향족 또는 비방향족 고리의 일부분을 형성할 수도 있다.
    R1, R2, R3, R4는수소원자, 할로겐, 저급 알킬 라디칼, 니트로 라디칼, 히드록실 라디칼, 알콕시 라디칼, 시아노 라디칼, 카르복실 라디칼, 카르복스아미도 라디칼, 알킬카르복실산염 라디칼, 아릴 또는 치환된 아릴 라디칼, 설포닉 라디칼, 선택적으로 아미노기가 치환될 수 있는 설폰아미도 라디칼 또는 아미노 또는 치환된 아미노 라디칼을 나타낸다.
    상기 식에서, Ar은 상술한 바와 같으며 X는 할로겐 원자를 나타낸다.
    상기 식에서 Z₁,Z₂ , Z₄및 R₃는 상술한 바와같다.
  2. 제 1항에 있어서, 상기 반응이 디메틸 설폭사이드, 디메텔 포름아미드, 에탄올 또는 프로판올류나 부탄올류중의 하나와 같은 알콕올, 방향족 또는 비방향족의 펩탄, 벤젠, 톨루엔과 같은 탄화수소, 디옥산이나 디페닐에테르와 같은 에테르로 된 적합한 용제 또는 이들 용제의 혼합물내에서 수행되는 것을 특징으로 하는 상기 제조방법.
  3. 제 2항에 있어서, 상기 용제가 디메틸포름아미드로 되는 것을 특징으로 하는 상기 제조방법.
  4. 제 1항 내지 제 3항 중 어느 한 항에 있어서, 상기 반응이 피리단, 트리에틸아민 또는 칼륨 tert-부톡사이드와 같은 유기 염기뿐만 아니라 알칼리금속 히드록사이드류, 탄산염류 또는 이탄산염류와 같은 무기염기나 혹은 이들 염기들의 혼합물의 존재하에서 수행되는 것을 특징으로 하는 상기 제조방법.
  5. 제 4항에 있어서, 상기 무기염기가 탄산칼륨으로 되는 것을 특징으로 하는 상기 제조방법.
  6. 제 1항 내지 제 5항 중 어느 한 항에 있어서, 상기 반응이 그 반응 온도는 실온에서 용제의 비등점온도사이, 더욱 바람직하기로는 80-160℃로 되고, 반응시간은 1-24시간으로 되는 것을 특징으로 하는 상기 제조방법.
  7. 제 1항에 있어서, 상기 일반식(Ⅰ)이 하기의 군으로부터 선택되는 것을 특징으로 하는 상기 화합물의 제조방법.
    1)1-{4-[4-(2-피리미디닐)-1-리페라지닐]-부틸}-피롤2)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-카아바졸3)1-{4-[4-(2-피리미디닐)-1-리페라지닐]-부틸}-인돌4)2,3-디페닐-1-{4-[4-(2-피리미디닐)-1-리페라지닐]-부틸}-인돌5)4-카르복스아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸6)4-카르복시-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸7)3-메틸-5-트리폴루오로메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피가졸8)4,5-디페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸9)2,4,5-디페닐-1-{4-[4-(2-피리미디닐)-1-리\피페라지닐]-부틸}-1H-이미다졸10)4,5-디페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸11)4,5-디클로로-2-메틸-1-{4-[4-(2-피리미디닐)-1-리페라지닐]-부틸}-1H-이미다졸12)2-에틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸13)2-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸14)메틸-1-{4-[4-(2-피리미디닐)-1-리페라지닐]-부틸}-1H-이미다졸-4-카르복실레이트15)4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸16)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸17)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-3H-이마다조[5,4-b]필리딘18)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다조[4,5-b]필리딘19)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤조트리아졸20)2-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이마다졸21)5-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸22)6-클로로-1-{4-[4-(2-피리미다닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸23)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-1,2,4-트리아졸24)2-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-2H-벤조트리아졸25)2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이마다졸26)5,6-디메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이마도졸27)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸28)3,5-디메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸29)3,5-디메틸-4-니트로-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸30)4-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 31)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-인다졸32)4-브로모-3,5-디메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸33)4-니트로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸34)4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸35)에틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸-4-카르복실레이트36)3-메틸-5-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸37)4-브로모-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸38)4-시아노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸39)4-플루오로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸40)4-메톡시-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸41)4-아미노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 42)4-메틸설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 43)4-벤즈아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸44)4-아세트아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸45)4-(2-부틸)아미노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸46)5-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸47)3-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸48)4-브로모-5-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸49)4-브로모-3-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸50)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-4,5,6,7-테트라히드로인다졸51)2-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-3,4,5,6-테트라히드로인다졸52)5-메틸-4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸53)3-메틸-4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸54)3-클로로-4-플루오로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸55)3-틀로로-4-메톡시-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸56)4-(4-메톡시페닐)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸57)4-(4-클로로페닐)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸58)4-(1-파이롤일)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸59)4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸60)3,5-디페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸61)4-페닐설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸62)4-(1-메틸벤젠)설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸63)4-부틸설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸64)4-포로필설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸65)4-에틸설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸66)3,5-디메틸-4-(N,N-디메틸설폰아미도)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸67)4-N-메틸설파모일-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸68)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸-4-설포닉69)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸70)2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸71)4,5-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸72)4-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸73)5-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸74)4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 75)4,5-디클로로-2-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸76)4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 77)4,5-디클로로-2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 78)4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸79)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피롤80)1-{4-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-1H-피롤 81)1-{4-[4-(페닐)-1-피페라지닐]-부틸}-1H-피롤 82)4-클로로-1-{4-[4-(페닐)-1-피페라지닐]-부틸}-1H-피라졸 83)4,5-디클로로-2-메틸-1-{4-[4-(페닐)-1-피페라지닐]-부틸}-1H-이미다졸84)4-클로로-1-{4-[4-(2-클로로페닐)-1-피페라지닐]-부틸}-1H-피라졸85)4,5-디클로로-2-메틸-1-{4-[4-(클로로페닐)-1-피페라지닐]-부틸}-1H-이미다졸86)4-클로로-1-{4-[4-(3-클로로페닐)-1-피페라지닐]-부틸}-1H-이미다졸87)1-{4-[4-(2-N-메틸이미다졸일)-1-피페라지닐]-부틸}-1H-피라졸88)4-클로로-1-{4-[4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐]-부틸}-1H-피라졸 89)4,5-디클로로-2-메틸-1-{4-[4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐]-부틸}-1H-이미다졸 90)4-브로모-1-{4-[4-(5-브로모피리미딘-2-일)-1-피페라지닐]-부틸}-1H-피라졸91)4-브로모-1-{4-[4-(5-클로로피리미단-2-일)-1-피페라지닐]-부틸}-1H-피라졸92)2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920003712A 1991-03-07 1992-03-06 아릴(또는 헤테로아릴) 피페라지닐부틸아졸 유도체의 제조방법 KR0124133B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9102735 1991-03-07
FR9102735A FR2673628B1 (fr) 1991-03-07 1991-03-07 Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.

Publications (2)

Publication Number Publication Date
KR920018046A true KR920018046A (ko) 1992-10-21
KR0124133B1 KR0124133B1 (ko) 1997-11-24

Family

ID=9410449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920003712A KR0124133B1 (ko) 1991-03-07 1992-03-06 아릴(또는 헤테로아릴) 피페라지닐부틸아졸 유도체의 제조방법

Country Status (17)

Country Link
US (1) US5227486A (ko)
EP (1) EP0502786B1 (ko)
JP (1) JP3084537B2 (ko)
KR (1) KR0124133B1 (ko)
AT (1) ATE137233T1 (ko)
AU (1) AU651177B2 (ko)
CA (1) CA2062468A1 (ko)
DE (1) DE69210076T2 (ko)
DK (1) DK0502786T3 (ko)
ES (1) ES2036145B1 (ko)
FR (1) FR2673628B1 (ko)
GR (1) GR3020341T3 (ko)
HU (1) HU219405B (ko)
NO (1) NO180376C (ko)
RU (1) RU2053230C1 (ko)
YU (1) YU48213B (ko)
ZA (1) ZA921682B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665161B1 (fr) * 1990-07-26 1992-11-27 Esteve Labor Dr Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5646281A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5521313A (en) * 1994-05-05 1996-05-28 Bristol-Myers Squibb Company Process for preparing certain azapirones
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
US6355659B1 (en) 1994-07-29 2002-03-12 Laboratorios Del Dr. Esteve, S.A. 4-(4-Chlorophenyl)-1236-tetrahydro-1(1H-124-triazol-1-yl)butty)pyrideine and salts thereof; pharmaceutical compositions and method of treating psychoses utilizing same
GB9500580D0 (en) * 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US6011052A (en) * 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
FR2763950B1 (fr) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU8125501A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
WO2002014315A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
CN1867336B (zh) 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
CA2428237C (en) * 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
EP1720545B1 (en) * 2004-03-03 2014-10-29 ChemoCentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2575180A1 (en) 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
JP2006169154A (ja) * 2004-12-15 2006-06-29 Sumitomo Chemical Co Ltd 第四級アンモニウム塩の製造方法
EP2924032B1 (en) * 2012-11-26 2019-03-06 Shenyang Haiwang Biotechnology Co., Ltd Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof
CN105669665A (zh) * 2016-03-15 2016-06-15 烟台贝森医药科技有限公司 哌罗匹隆的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1279645C (en) * 1986-02-27 1991-01-29 Ineke Van Wijngaarden Aryl-substituted (n-piperidinyl)methyl- and (n-piperazinyl)methylazoles having antipsychotic properties
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
US5077293A (en) * 1990-06-29 1991-12-31 Bristol-Myers Squibb Co. 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines

Also Published As

Publication number Publication date
YU48213B (sh) 1997-08-22
EP0502786B1 (fr) 1996-04-24
DE69210076T2 (de) 1996-10-24
ES2036145A1 (es) 1993-05-01
NO180376B (no) 1996-12-30
JP3084537B2 (ja) 2000-09-04
RU2053230C1 (ru) 1996-01-27
HU9200768D0 (en) 1992-05-28
YU21592A (sh) 1994-06-24
ZA921682B (en) 1992-11-25
NO920888D0 (no) 1992-03-06
AU651177B2 (en) 1994-07-14
ATE137233T1 (de) 1996-05-15
HU219405B (hu) 2001-04-28
FR2673628B1 (fr) 1993-07-09
HUT60731A (en) 1992-10-28
GR3020341T3 (en) 1996-09-30
JPH0578313A (ja) 1993-03-30
KR0124133B1 (ko) 1997-11-24
ES2036145B1 (es) 1994-10-16
DK0502786T3 (da) 1996-05-13
DE69210076D1 (de) 1996-05-30
FR2673628A1 (fr) 1992-09-11
EP0502786A1 (fr) 1992-09-09
NO920888L (no) 1992-09-08
AU1142992A (en) 1992-09-10
US5227486A (en) 1993-07-13
CA2062468A1 (en) 1992-09-08
NO180376C (no) 1997-04-09

Similar Documents

Publication Publication Date Title
KR920018046A (ko) 아릴(또는 헤테로아릴)피페라지닐부틸아졸 유도체의 제조방법
KR920014804A (ko) 아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용
KR870003099A (ko) 헤테로 고리치환인돌 및 그의 중간체 제조방법 및 이를 포함한 약제조성물
KR950032138A (ko) 벤즈이미다졸, 이 화합물을 함유하는 약제학적 조성물 및 이의 제조방법
YU48071B (sh) DERIVTI (w/4-(2-PIRIMIDINIL)-1-PIPERAZINIL/ALKIL)-1H-AZOLA I POSTUPAK NJIHOVOG DOBIJANJA
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
NZ215175A (en) Barbituric acid derivatives and anthelmintic compositions
Fahim et al. Sun degradation and synthesis of new antimicrobial and antioxidant utilising poly (ethylene terephthalate) waste
CA2194563A1 (en) Anti-helicobacter heterocyclic derivatives of azolones
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
Abass et al. Substituted Pyridopyrimidinones. Part 3.: Synthesis of Some Novel Ether Derivatives of 4H-Pyrido [1, 2-a] pyrimidin-4-one
Sergievskii et al. 4-Aminofurazan-3-carboxylic acid iminoester in reactions with N, O-nucleophiles
Rooney et al. 5-Aryl-4-hydroxy-3 (2H)-isothiazolone 1, 1-dioxide derivatives. Synthesis and carbon-13 NMR characterization
RU98117846A (ru) Способ связывания тиолов

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010905

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee